Therapeutic anti-coagulation in COVID-19 and the potential enhanced risk of retroperitoneal hematoma

Abstract

It has been well established in the literature that those with COVID-19 are at increased risk of thrombotic disease, however, research into the best modalities to therapeutically anti-coagulate patients in this population is on-going. This case series highlights concerns with regard to possible increased rates of life-threatening bleeding in this population.